Strs Ohio boosted its position in Blueprint Medicines Corp (NASDAQ:BPMC) by 69.6% during the 4th quarter, HoldingsChannel reports. The firm owned 3,900 shares of the biotechnology company’s stock after purchasing an additional 1,600 shares during the quarter. Strs Ohio’s holdings in Blueprint Medicines were worth $294,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wells Fargo & Company MN lifted its stake in Blueprint Medicines by 31.5% in the 2nd quarter. Wells Fargo & Company MN now owns 28,827 shares of the biotechnology company’s stock worth $1,462,000 after purchasing an additional 6,899 shares in the last quarter. Alyeska Investment Group L.P. purchased a new stake in Blueprint Medicines in the 3rd quarter worth approximately $6,967,000. California Public Employees Retirement System purchased a new stake in Blueprint Medicines in the 2nd quarter worth approximately $314,000. Ameriprise Financial Inc. purchased a new stake in shares of Blueprint Medicines during the 3rd quarter valued at $3,779,000. Finally, California State Teachers Retirement System raised its position in shares of Blueprint Medicines by 43.9% during the 2nd quarter. California State Teachers Retirement System now owns 68,861 shares of the biotechnology company’s stock valued at $3,489,000 after buying an additional 20,999 shares in the last quarter. Institutional investors and hedge funds own 83.79% of the company’s stock.

Blueprint Medicines Corp (BPMC) opened at $73.67 on Tuesday. The company has a current ratio of 11.28, a quick ratio of 11.28 and a debt-to-equity ratio of 0.02. Blueprint Medicines Corp has a twelve month low of $32.43 and a twelve month high of $92.00. The company has a market cap of $3,199.91, a price-to-earnings ratio of -21.60 and a beta of 1.16.

In related news, insider Marion Dorsch sold 18,334 shares of the stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $65.45, for a total transaction of $1,199,960.30. Following the transaction, the insider now owns 18,334 shares of the company’s stock, valued at approximately $1,199,960.30. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Daniel Lynch sold 5,000 shares of the stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $63.38, for a total transaction of $316,900.00. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by company insiders.

Several research firms have recently weighed in on BPMC. Zacks Investment Research upgraded shares of Blueprint Medicines from a “hold” rating to a “buy” rating and set a $88.00 price objective on the stock in a research report on Monday, January 15th. Goldman Sachs Group raised their price objective on shares of Blueprint Medicines from $82.00 to $99.00 and gave the company a “buy” rating in a research report on Monday, December 11th. Raymond James Financial set a $82.00 price objective on shares of Blueprint Medicines and gave the company a “buy” rating in a research report on Sunday, December 10th. JMP Securities raised their price objective on shares of Blueprint Medicines from $88.00 to $97.00 and gave the company an “outperform” rating in a research report on Monday, December 11th. Finally, BidaskClub cut shares of Blueprint Medicines from a “buy” rating to a “hold” rating in a research report on Wednesday, December 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $84.20.

ILLEGAL ACTIVITY NOTICE: This story was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://theolympiareport.com/2018/02/13/blueprint-medicines-corp-bpmc-holdings-increased-by-strs-ohio.html.

Blueprint Medicines Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Corp (NASDAQ:BPMC).

Institutional Ownership by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.